2026–2027 Influenza, RSV, and SARSCoV-2 Immunization Recommendations for Nonpregnant, Immunocompetent Adults and Health Care Personnel

Published online October 16, 2026.

Margot Savoy, MD, MPH
Corban Wehr, BGS

American Family Physician. 2026;114(5):527B-527K.

Author Disclosure: No relevant financial relationships.

This immunization guidance from the American Academy of Family Physicians (AAFP) addresses nonpregnant, immunocompetent adults 19 years and older and health care personnel. For other populations, see guidance from the American Academy of Pediatrics (for individuals 18 years and younger), Infectious Diseases Society of America (for individuals with immunocompromise), and American College of Obstetricians and Gynecologists (for pregnant individuals). Recommendations in this document are guided by the AAFP Adult Immunization Schedule. Where AAFP guidance differs from other organizations, the AAFP recommendation should be followed. AAFP immunization recommendations are reviewed and approved annually.

SUMMARY OF AAFP CLINICAL RECOMMENDATIONS

  • All adults 19 years and older should receive an annual influenza vaccine and an updated COVID-19 vaccine.
  • Adults 65 years and older should preferentially receive an enhanced influenza vaccine (high dose, adjuvanted, recombinant, or mRNA) when available, but vaccination should not be delayed if one is unavailable.
  • Adults 65 years and older should receive two doses of the updated COVID-19 vaccine each season, with the first at month 0 and the second 6 months later.
  • Adults 75 years and older and adults 50 to 74 years of age who are at increased risk should receive one dose of the respiratory syncytial virus (RSV) vaccine.
  • Health care personnel should receive annual influenza and updated COVID-19 vaccination due to their repeated occupational exposure and contact with patients at high risk of severe disease.

WHY RESPIRATORY IMMUNIZATION IS RELEVANT THIS SEASON

Fall and winter respiratory season brings sharply elevated risk from three vaccine-preventable viruses: influenza, RSV, and SARS-CoV-2. In a Danish nationwide cohort of adults, RSV and influenza each accounted for substantial hospitalizations, with the risk concentrated in older adults and those with chronic cardiopulmonary disease, confirming that RSV burden in adults is comparable with that of influenza rather than incidental to it.2 US surveillance through the Respiratory Virus Hospitalization Surveillance Network (RESP-NET) tracks the three viruses and consistently identifies adults 65 years and older as being at highest risk for hospitalization and death.3

Younger adults with chronic conditions (eg, diabetes, obesity, chronic lung disease, cardiovascular disease) also experience substantial respiratory-related hospitalization; healthy younger adults contribute to community transmission.2,4 The recommendations in this document address all adults 19 years and older, not only those at highest risk.

Vaccine uptake remains well below where it should be, including in the highest-risk group. During the 2024–2025 influenza season, only 41.9% of adults 18 years and older and 64% of adults 65 years and older received an influenza vaccine.5 As of January 2026, 16.1% of adults had received a 2025–2026 COVID-19 vaccine, and 43.9% had received a 2025–2026 influenza vaccine.6 RSV vaccine–uptake rates among eligible older adults were similarly low. As of February 2026, 40.9% of adults 75 years and older and 30.9% of adults 50 to 74 years with high-risk conditions reported ever receiving an RSV vaccine.6

Immunization remains the most effective intervention to reduce severe respiratory illness.7 This document provides current AAFP recommendations, product guidance, and practical workflows for delivering vaccines efficiently in primary care.

INFLUENZA VACCINATION IN NONPREGNANT, IMMUNOCOMPETENT ADULTS 19 YEARS AND OLDER

MARGOT SAVOY, MD, MPH, FAAFP, is chief medical officer of the American Academy of Family Physicians in Leawood, Kansas, and an adjunct professor of family medicine at Georgetown University School of Medicine, Washington, District of Columbia.

CORBAN WEHR, BGS, is a clinical health policy strategist in the Health of the Public and Science division of the American Academy of Family Physicians, Leawood, Kansas.

Address correspondence to Corban Wehr, BGS, at cwehr@aafp.org.

Author Disclosure: No relevant financial relationships.

  1. 1.American Academy of Family Physicians. Adults 19 and older immunization schedule. Accessed August 7, 2026. https://www.aafp.org/clinical-insights/immunizations-and-vaccines/immunizations-schedules-resources/adult-immunization-schedules​
  2. 2.Fonseca MJ, Bratković S, Pedersen M, et al. Burden of respiratory syncytial virus and influenza in adults —a Danish nationwide cohort study. Clin Microbiol Infect. 2026;32(6):1006-1014.
  3. 3.Centers for Disease Control and Prevention. Respiratory Virus Hospitalization Surveillance Network (RESP-NET). January 30, 2026. Accessed August 7, 2026. https://www.cdc.gov/resp-net/dashboard/index.html​
  4. 4.Goldberg R. Chronic conditions linked to severe outcomes in younger adults with influenza. January 5, 2024. Accessed August 7, 2026. https://www.pulmonologyadvisor.com/news/younger-adults-with-chronic-conditions-have-severe-influenza-outcomes​
  5. 5.Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2024–25 influenza season. January 8, 2026. Accessed August 7, 2026. https://www.cdc.gov/fluvaxview/coverage-by-season/2024-2025.html​
  6. 6.Centers for Disease Control and Prevention. Vaccination uptake, intent, and confidence. February 20, 2026. Accessed August 7, 2026. https://www.cdc.gov/respvaxview/dashboards/vaccination-behavioral-social-drivers.html​
  7. 7.Centers for Disease Control and Prevention. Respiratory illness season toolkit. February 27, 2026. Accessed August 7, 2026. https://www.cdc.gov/respiratory-viruses/php/toolkit/index.html​
  8. 8.Centers for Disease Control and Prevention. Flu and people 65 years and older. September 4, 2026. Accessed October 7, 2026. https://www.cdc.gov/flu/highrisk/65over.htm​
  9. 9.Hsiao A, Leong T, Fireman B, et al. Adjuvanted vs high-dose influenza vaccines in older US adults: a cluster randomized crossover study. JAMA Netw Open. 2026;9(5):e2610120.
  10. 10.Qaseem A, Wilt TJ, Harrod CS, et al.; Population Health and Medical Science Committee of the American College of Physicians. Influenza vaccines for 2025–2026 in adults who are not pregnant or immunocompromised: rapid practice points from the American College of Physicians. Ann Intern Med. 2026;179(1):110-117.
  11. 11.Pardo-Seco J, Rodríguez-Tenreiro-Sánchez C, Giné-Vázquez I, et al.; GALFLU Trial Team. High-dose influenza vaccine to reduce hospitalizations. N Engl J Med. 2025;393(23):2303-2312.
  12. 12.Johansen ND, Modin D, Loiacono MM, et al. High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults: a prespecified secondary analysis of the DANFLU-2 randomized clinical trial. JAMA Cardiol. 2025;10(11):1186-1194.
  13. 13.Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. July 24, 2024. Accessed August 7, 2026. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html​
  14. 14.mFlusiva. Prescribing information. Moderna; August 2026. Accessed August 7, 2026. https://www.fda.gov/media/194120/download
  15. 15.BioPharm International Staff. Moderna's mFLUSIVA approval validates mRNA platform beyond COVID-19: what it means for biopharmaceutical manufacturing. August 6, 2026. Accessed August 7, 2026. https://www.biopharminternational.com/view/moderna-mflusiva-approval-validates-mrna-platform-beyond-covid-19-what-it-means-for-biopharmaceutical-manufacturing​
  16. 16.Centers for Disease Control and Prevention. Fluzone high-dose seasonal influenza vaccine. June 11, 2026. Accessed August 7, 2026. https://www.cdc.gov/flu/vaccine-types/flu-zone.html​
  17. 17.Centers for Disease Control and Prevention. Adjuvanted flu vaccine. September 1, 2026. Accessed October 7, 2026. https://www.cdc.gov/flu/vaccine-types/adjuvant.html​
  18. 18.Centers for Disease Control and Prevention. Recombinant influenza (flu) vaccine. June 16, 2026. Accessed August 7, 2026. https://www.cdc.gov/flu/vaccine-types/flublok-vaccine.html​
  19. 19.Centers for Disease Control and Prevention. People at increased risk for flu complications. September 11, 2024. Accessed August 7, 2026. https://www.cdc.gov/flu/highrisk/index.htm​
  20. 20.Li T, Qi X, Li Q, et al. A systematic review and meta-analysis of seasonal influenza vaccination of health workers. Vaccines (Basel). 2021;9(10):1104.
  21. 21.Ahmed F, Lindley MC, Allred N, et al. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: systematic review and grading of evidence. Clin Infect Dis. 2014;58(1):50-57.
  22. 22.Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 influenza season. MMWR Morb Mortal Wkly Rep. 2025;74(32):500-507.
  23. 23.Kemp A. FluMist approved for self-administration in the US. September 20, 2024. Accessed July 28, 2026. https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html​
  24. 24.Gallagher A. Ongoing AAP, HHS legal battle will determine future health care action. June 4, 2026. Accessed August 7, 2026. https://www.drugtopics.com/view/ongoing-aap-hhs-legal-battle-will-determine-future-health-care-action​
  25. 25.Centers for Disease Control and Prevention. Thimerosal and vaccines. October 28, 2025. Accessed August 7, 2026. https://www.cdc.gov/vaccine-safety/about/thimerosal.html​
  26. 26.U.S. Food and Drug Administration. Influenza vaccine composition for the 2026–2027 U.S. influenza season. March 13, 2026. Accessed August 7, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-vaccine-composition-2026-2027-us-influenza-season​
  27. 27.U.S. Food and Drug Administration. Use of trivalent influenza vaccines for the 2024–2025 U.S. influenza season. March 5, 2024. Accessed August 7, 2025. https://www.fda.gov/vaccines-blood-biologics/lot-release/use-trivalent-influenza-vaccines-2024-2025-us-influenza-season​
  28. 28.Centers for Disease Control and Prevention. Interim clinical considerations for the use of seasonal influenza vaccines in the United States. September 1, 2026. Accessed October 8, 2026. https://www.cdc.gov/flu/hcp/vax-summary/acip-recommendations.html​
  29. 29.Centers for Disease Control and Prevention. Seasonal influenza vaccine dosage and administration. May 12, 2026. Accessed August 7, 2026. https://www.cdc.gov/flu/hcp/vax-summary/vaccine-dosage-admin.html​
  30. 30.U.S. Food and Drug Administration. 191st Vaccines and Related Biological Products Advisory Committee meeting. March 12, 2026. Accessed October 7, 2026. https://www.fda.gov/media/192383/download​
  31. 31.U.S. Food and Drug Administration. COVID-19 vaccines (2026–2027 formula) for use in the United States beginning in fall 2026. May 29, 2026. Accessed August 7, 2026. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2026-2027-formula-use-united-states-beginning-fall-2026​
  32. 32.Splete H. FDA advisors favor dominant US strain, XFG, for next COVID vaccine. May 29, 2026. Accessed August 7, 2026. https://www.medscape.com/viewarticle/fda-advisors-favor-dominant-us-strain-xfg-next-covid-vaccine-2026a1000i01​
  33. 33.Thompson MG, Cowling BJ. How repeated influenza vaccination effects might apply to COVID-19 vaccines. Lancet Respir Med. 2022;10(7):636-638.
  34. 34.Wiegand RE, Chickery S, Yang DH, et al. Interim estimated effectiveness of 2025–2026 COVID-19 vaccines in adults using a test-negative design. JAMA Netw Open. 2026;9(6):e2625152.
  35. 35.Centers for Disease Control and Prevention. People with certain medical conditions and COVID-19 risk factors. October 8, 2026. Accessed October 16, 2026. https://www.cdc.gov/covid/risk-factors/index.html​
  36. 36.Ma KC, Webber A, Lauring AS, et al.; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. Estimated effectiveness of 2024–2025 COVID-19 vaccination against severe COVID-19. JAMA Netw Open. 2026;9(2):e2557415.
  37. 37.Ioannou GN, Berry K, Yan L, et al. Effectiveness of the 2024–2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up. Nat Commun. 2025;17(1):1043.
  38. 38.Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024–2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(49):1118-1123.
  39. 39.U.S. Food and Drug Administration. Vaccines licensed for use in the United States. October 8, 2026. Accessed October 16, 2026. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states​
  40. 40.Stein R. The latest COVID vaccines come with new FDA limits. August 27, 2025. Accessed August 7, 2026. https://www.npr.org/sections/shots-health-news/2025/08/27/nx-s1-5515503/fda-covid-vaccines-restricted​
  41. 41.AHIP statement on vaccine coverage. Updated May 2026. Accessed July 28, 2026. https://www.ahip.org/news/press-releases/ahip-statement-on-vaccine-coverage​
  42. 42.Centers for Disease Control and Prevention. RSV vaccine guidance for adults. February 24, 2026. Accessed August 7, 2026. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html​
  43. 43.Bajema KL, Bui DP, Yan L, et al. Durability of respiratory syncytial virus vaccine effectiveness among US veterans. JAMA Intern Med. 2026;186(1):78-88.
  44. 44.Lassen MCH, Johansen ND, Christensen SH, et al. Bivalent RSV prefusion F protein-based vaccine for preventing cardiovascular hospitalizations in older adults: a prespecified analysis of the DANRSV trial. JAMA. 2025;334(16):1431-1441.
  45. 45.Arexvy. Prescribing information. GlaxoSmithKline; July 2026. Accessed August 7, 2026. https://www.fda.gov/media/167805/download​
  46. 46.Abrysvo. Prescribing information. Pfizer; December 2025. Accessed August 7, 2026. https://www.fda.gov/media/168889/download​
  47. 47.mResvia. Prescribing information. Moderna; August 2026. Accessed August 7, 2026. https://www.fda.gov/media/179005/download​
  48. 48.Reuters. GSK gets US FDA approval for expanded use of RSV vaccine. Updated March 13, 2026. Accessed August 7, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-gets-us-fda-approval-expanded-use-rsv-vaccine-2026-03-13​
  49. 49.Pfizer Medical. Abrysvo 2 dosage and administration. Accessed October 8, 2026. https://www.pfizermedical.com/abrysvo/dosage-admin
  50. 50.Senerth E, Sheikholeslamian SM, Babatunde I, et al. RSV immunization effectiveness and safety for the 2026–2027 respiratory season. JAMA. Published online September 2, 2026. Accessed October 7, 2026. https://www.jamanetwork.com/journals/JAMA/fullarticle/2853780​
  51. 51.Hause AM, Moro PL, Baggs J, et al. Early safety findings among persons aged ≥60 years who received a respiratory syncytial virus vaccine—United States, May 3, 2023–April 14, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(21):489-494.
  52. 52.Scott J, Abers MS, Marwah HK, et al. Updated evidence for Covid-19, RSV, and influenza vaccines for 2025–2026. N Engl J Med. 2025;393(22):2221-2242.
  53. 53.Ferguson M, Schwarz TF, Núñez SA, et al. Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50–59 years of age, including at-increased-risk adults: a randomized controlled trial. Hum Vaccin Immunother. 2025;21(1):2579335.
  54. 54.American Academy of Family Physicians. Immunizations. December 13, 2019. Accessed August 7, 2026. https://www.aafp.org/about/policies/immunizations
  55. 55.Davies SR, Davies AL, Higgins JPT, et al. Effectiveness of interventions to increase vaccine uptake: component network meta-analysis. BMJ. 2026;393:e087578.
  56. 56.Wheeler SG, Beste LA, Overland MK, et al. Interventions in primary care to increase uptake of adult vaccines: a systematic review. J Public Health (Oxf). 2025;47(2):222-231.
  57. 57.Wolf J. New AAFP resources strengthen adult immunization conversations. AAFP blog. August 3, 2026. Accessed August 7, 2026. https://www.aafp.org/about/blog/new-aafp-resources-strengthen-adult-immunization-conversations
  58. 58.Elwyn G, Gulbrandsen P, Leavitt H, et al. Shared decision-making. A primer for clinicians. J Gen Intern Med. 2025;40(16):3889-3899.
  59. 59.Parker CE, Hause AM, Marquez P, et al. Trends in the administration of COVID-19 vaccines with other vaccines in the United States reported to V-safe during December 14, 2020–May 19, 2023. Hum Vaccin Immunother. 2024;20(1):2361946.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.